Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

ClinicalTrials.gov ID: NCT00614614

Public ClinicalTrials.gov record NCT00614614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 20, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Meningococcal Vaccine 134612 Given at 12-15 Months of Age or at 15-18 Months of Age (Co-administered With Infanrix®) in Primed Healthy Toddlers.

Study identification

NCT ID
NCT00614614
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,558 participants

Conditions and interventions

Interventions

  • GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix) Biological
  • GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix) Biological
  • Infanrix® Biological
  • ActHIB® Biological
  • Pediarix® Biological

Biological

Eligibility (public fields only)

Age range
6 Weeks to 12 Weeks
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 12, 2008
Primary completion
Jul 30, 2009
Completion
Sep 16, 2009
Last update posted
Sep 20, 2018

2008 – 2009

United States locations

U.S. sites
56
U.S. states
23
U.S. cities
53
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205
GSK Investigational Site Birmingham Alabama 35244
GSK Investigational Site Dothan Alabama 36305
GSK Investigational Site Benton Arkansas 72019
GSK Investigational Site Fayetteville Arkansas 72703
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Fresno California 93726
GSK Investigational Site Huntington Beach California 92647
GSK Investigational Site West Covina California 91790
GSK Investigational Site Plantation Florida 33324
GSK Investigational Site West Palm Beach Florida 33407
GSK Investigational Site Marietta Georgia 30062
GSK Investigational Site Woodstock Georgia 30189
GSK Investigational Site Nampa Idaho 208 463 3126
GSK Investigational Site Des Moines Iowa 50312
GSK Investigational Site West Des Moines Iowa 50266
GSK Investigational Site Arkansas City Kansas 67005
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Lexington Kentucky 40503
GSK Investigational Site Bossier City Louisiana 71111
GSK Investigational Site Boston Massachusetts 02130
GSK Investigational Site Fall River Massachusetts 02724
GSK Investigational Site Kalamazoo Michigan 49008
GSK Investigational Site Niles Michigan 49120
GSK Investigational Site Portage Michigan 49024
GSK Investigational Site Richland Michigan 49083
GSK Investigational Site Stevensville Michigan 49127
GSK Investigational Site Saint Paul Minnesota 55108
GSK Investigational Site Henderson Nevada 89015
GSK Investigational Site Clyde North Carolina 28721
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Cleveland Ohio 44121
GSK Investigational Site Huber Heights Ohio 45424
GSK Investigational Site Gresham Oregon 97030
GSK Investigational Site Erie Pennsylvania 16505
GSK Investigational Site Greenville Pennsylvania 16125
GSK Investigational Site Pittsburgh Pennsylvania 15220
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Pittsburgh Pennsylvania 15241
GSK Investigational Site Uniontown Pennsylvania 15401
GSK Investigational Site Charleston South Carolina 29406
GSK Investigational Site Kingsport Tennessee 37660
GSK Investigational Site Amarillo Texas 79124
GSK Investigational Site Galveston Texas 77555-1119
GSK Investigational Site Sugar Land Texas 77479
GSK Investigational Site Layton Utah 84041
GSK Investigational Site Ogden Utah 84405
GSK Investigational Site Orem Utah 84057
GSK Investigational Site Provo Utah 84604
GSK Investigational Site Roy Utah 84067
GSK Investigational Site South Jordan Utah 84095
GSK Investigational Site St. George Utah 84790
GSK Investigational Site Syracuse Utah 84075
GSK Investigational Site Marshfield Wisconsin 54449

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00614614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 20, 2018 · Synced Jul 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00614614 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →